Within a year, 3 deputy general managers of the pharmaceutical company left! In 2021, the pre-tax remuneration will exceed 4 million yuan

Since the beginning of this year, senior executives in the pharmaceutical industry have changed frequently, and some executives of pharmaceutical companies have even frequently "left"
.
Among them, Hengrui Pharmaceutical has resigned three deputy general managers since the beginning of the year, namely Tao Weikang, Zou Jianjun and Zhang Yuehong
.
Specifically, on the evening of October 10, Hengrui Pharmaceutical announced a personnel change
.
According to the announcement, Tao Weikang, deputy general manager of the company, resigned due to personal reasons, and after his resignation, Tao Weikang will no longer hold any position in the company, and the relevant work he is responsible for has been handed over
.
It is understood that Tao Weikang has been engaged in new drug research and development in Merck Pharmaceutical Company in the United States for more than ten years, serving as a senior researcher and department head, and presided over the research and development and project management
of a number of new anti-cancer drugs.
He has served as the deputy general manager of Shanghai Hengrui Pharmaceutical Co.
, Ltd.
and the CEO of the R&D center since 2014, and has been the deputy general manager of the company since July 2015, On April 12, Hengrui Pharmaceutical issued an announcement that Zou Jianjun applied to resign from the position of deputy general manager of the company for personal reasons, and after his resignation, Zou Jianjun no longer held any position
in the company 。 According to the data, Zou Jianjun once served as the head of the Chinese oncology treatment team at Bayer China, and then served as the global medical affairs head of the oncology product Xofigo at Bayer headquarters, and also served as the medical affairs head of Celgene Pharmaceutical, where he joined Hengrui Pharmaceutical in September 2015 and has worked here for more than
6 years.
During the period, Hengrui Pharmaceutical launched 7 innovative drugs and 17 new indications, including thiopegrastim, pyrrotinib, carrelizumab, fluzoparib, hytrombopagallamine, darcilib, hengagliflozin, etc
.
Earlier, on February 25, the company said that the board of directors had received a resignation report
from Zhang Yuehong, the company's deputy general manager.
Zhang Yuehong applied to resign from the position of deputy general manager of the company due to personal reasons, and the resignation report took effect
from the date of delivery to the board of directors of the company.
After resigning from the above position, Zhang Yuehong no longer holds any position
in the company.
In terms of salary, the pre-tax compensation of these three managers in 2021 will exceed 4 million yuan, 4.
5334 million yuan, 5.
7761 million yuan and 4.
8438 million yuan
respectively.
However, there have been executive departures and new executives
.
For example, on October 10, Hengrui Pharmaceutical appointed He Feng, who had worked at Bristol-Myers Squibb, Novartis and AbbVie, engaged in the research and development of innovative drugs in the fields of viruses, cancer, kidney diseases and other diseases, as the deputy general manager of Hengrui Pharmaceutical, who will undertake the new drug research and development and R&D management of Shanghai Hengrui R&D Center; On April 12, Hengrui Pharmaceutical announced the appointment of Zhang Xiaojing as deputy general manager and chief medical executive officer (oncology), and appointed Wang Quan as deputy general manager
.
According to the data, Hengrui Pharmaceutical's main business involves drug research and development, production and sales, and its main products cover antitumor drugs, surgical anesthesia drugs, contrast agents, special infusions, cardiovascular drugs and many other fields
.
According to the 2021 annual report, Hengrui Pharmaceutical achieved revenue of 25.
906 billion yuan, a year-on-year decrease of 6.
59%, and the net profit attributable to shareholders of listed companies was 4.
530 billion yuan, a year-on-year decrease of 28.
41%.

In the first half of 2022, the company's revenue was 10.
228 billion yuan, down 23.
08% from the same period of the previous year; The net profit attributable to the owners of the parent company was 2.
119 billion yuan, down 20.
55%
from the same period of the previous year.
Some people believe that due to factors such as collective procurement, medical insurance negotiations, and the epidemic, Hengrui's performance has been under pressure in recent years, and in order to accelerate the company's transformation and development, executive changes will be more conducive to stimulating team vitality and increasing transformation momentum
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.